UPLOAD Filing
Inhibikase Therapeutics, Inc.
Date: June 25, 2025 · CIK: 0001750149 · Accession: 0000000000-25-006615
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-288213
Letter
Re: Inhibikase Therapeutics, Inc. Registration Statement on Form S-3 Filed June 20, 2025 File No. 333-288213 Dear Mark Iwicki:
June 25, 2025
Mark Iwicki Chief Executive Officer Inhibikase Therapeutics, Inc. 1000 N. West Street, Suite 1200 Wilmington, DE 19801
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Marishka DeToy
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> June 25, 2025 Mark Iwicki Chief Executive Officer Inhibikase Therapeutics, Inc. 1000 N. West Street, Suite 1200 Wilmington, DE 19801 Re: Inhibikase Therapeutics, Inc. Registration Statement on Form S-3 Filed June 20, 2025 File No. 333-288213 Dear Mark Iwicki: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Marishka DeToy </TEXT> </DOCUMENT>